Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high-quality biosimilar medicines.
Our true purpose as a company is to make people's lives better by producing high quality medicines that help people live longer, healthier and more active lives and by making medicine more accessible to those who might not otherwise be able to afford them.
Follow news and programs from Alvotech around the world as they unfold.
Our biosimilar assets include various biosimilar monoclonal antibodies that are developed in our four R&D centers located across Europe and are manufactured in our state-of-the-art facility located in Reykjavik, Iceland.
Our state-of-the-art facility is designed and built to meet highest FDA and EMA GMP requirements globally. Alvotech’s primary focus is on safety, compliance and flexibility.
Alvotech’s international team currently includes over 400 scientists and professionals working at the company’s state-ofthe-art biosimilar facility and headquarters in Reykjavik, Iceland, three other development centers in Hannover and Jülich in Germany as well as Zurich in Switzerland.